Trial reportAmerican journal of respiratory and critical care medicine2023
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2025Trial
- Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives.Clinical and translational science · 2024Trial
- Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research.Pharmaceutics · 2026Review
- RNA splicing in health and disease.Molecular biomedicine · 2026Review
- Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans.Pharmaceutical research · 2026Article
- Epithelial plasma membrane transporters as drug targets.Physiological reviews · 2026Review
- Review
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Breaking boundaries or a small piece of the puzzle: can CFTR modulators transform bronchiectasis care?ERJ open research · 2025Article
- Recent developments in cystic fibrosis drug discovery: where are we today?Expert opinion on drug discovery · 2025Review
- Therapeutic strategies to reverse cigarette smoke-induced ion channel and mucociliary dysfunction in COPD airway epithelial cells.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- ERS Congress 2024: highlights from the Respiratory Infections Assembly.ERJ open research · 2025Article
- Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- CFTR expression decreases with age in several airway cell types.Scientific reports · 2024Article
- Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.American journal of respiratory and critical care medicine · 2024Review
- Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells.Respiratory research · 2024Article
- Article
- Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?International journal of molecular sciences · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 14 institutions in 9 countries.
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York.ORCID 0000-0002-2412-3182
Gerard J CrinerDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
Christian GessnerInstitute for Clinical Immunology, University of Leipzig, Leipzig, Germany.
Margret JandlHamburger Institut für Therapieforschung GmbH, Hamburg, Germany.
Fernando ScherbovskyFundación Scherbovsky, Mendoza, Argentina.
Masaharu ShinkaiDepartment of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan.
Thomas M SilerMidwest Chest Consultants, PC, St. Charles, Missouri.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research, Marburg, Germany.
Robert VovesPrivate Practice, Bismarckstraße, Feldbach, Austria.
Jadwiga A WedzichaNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Christian BartelsNovartis Pharma AG, Basel, Switzerland.
Ivan BottoliNovartis Pharma AG, Basel, Switzerland.
Stuart ByiersNovartis Pharma AG, Basel, Switzerland.
Pamela CardenasNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Joerg H EckertNovartis Pharma AG, Basel, Switzerland.
Florian S GutzwillerNovartis Pharma AG, Basel, Switzerland.
Barbara KnorrNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Mahavir KothariNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Rutvick ParlikarNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Ana-Maria TanaseNovartis Pharma AG, Basel, Switzerland.
Frits M E FranssenDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
Novartis (Switzerland) · CHNovartis (India) · INNovartis (United States) · USAmerican College of Chest Physicians · USGerman Center for Lung Research · DEHamburg Institute for Therapy Research · DEImperial College London · GBLandeskrankenhaus Feldkirch · ATLeipzig University · DEMaastricht University Medical Centre · NLNew Tokyo Hospital · JPNewYork–Presbyterian Hospital · USTemple University · USUniversity of Mendoza · AR
Funding
Medical Research Council G0800570Medical Research Council G1001365
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bronchitis, ChronicPulmonary Disease, Chronic ObstructiveAmidesCoughCystic Fibrosis Transmembrane Conductance RegulatorDouble-Blind MethodForced Expiratory VolumeHumansPyridinesTreatment OutcomeAmidesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatoricenticaftorPyridinesCFTR dysfunctionCFTR potentiatorchronic bronchitisCOPDicenticaftor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.